News & Perspective

(CIDRAP News) – At an Infectious Diseases Society of America (IDSA) symposium in Washington, DC, today on seasonal and pandemic influenza, a group of experts fielded questions from reporters on some of the new trends and emerging issues, including prepandemic strategies for H5N1 avian influenza vaccines, now that some countries are stockpiling them.

(CIDRAP News) – An H5N1 influenza vaccine made by Baxter International could become the first cell culture–based H5N1 influenza vaccine to be approved for marketing, following its endorsement by a committee of the European Medicines Agency (EMEA) last week.

Recommendations of the Committee for Medicinal Products for Human Use (CHMP) are usually followed by the EMEA within a few months.

(CIDRAP News) – The world is far from being well prepared for an influenza pandemic, leading national and international health officials warned at a meeting in Malaysia last week.

As the H5N1 avian influenza virus continues to thrive in birds, there is no vaccine that can provide sure protection if it evolves into a pandemic strain, and governments are paying less attention to the threat, officials said.

(CIDRAP News) – David Nabarro, influenza coordinator for the United Nations (UN), said during a press conference yesterday that the world is better prepared to respond to an influenza pandemic, but he added that continuing outbreaks in some countries are a reminder that a major threat remains.

(CIDRAP News) – A pharmaceutical company is reporting good results in the first clinical trial of an H5N1 avian influenza vaccine that uses a whole, killed H5N1 virus grown in cell culture—a combination of techniques that entails some risk but may boost immune response and shorten production time.

(CIDRAP News) – An H5N1 influenza vaccine based on a weakened adenovirus was tested successfully in mice and may offer advantages as a tool for combating a human flu pandemic, according to researchers from the Centers for Disease Control and Prevention (CDC) and Purdue University.

(CIDRAP News) – The US Department of Health and Human Services (HHS) has accepted the first batch of H5N1 avian influenza vaccine based on the H5N1 variant known as clade 2.2, which has spread most widely across Asia, Europe, and Africa.